# Evaluation of Quality of Life and Survival With MS-20 in Patient With Advanced Hepatocellular Carcinoma (FDA IND 74572)

> **NCT00707681** · PHASE2 · UNKNOWN · sponsor: **Microbio Co Ltd** · enrollment: 60 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** MS-20
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00707681
- **Lead sponsor:** Microbio Co Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-03
- **Primary completion:** 2010-12
- **Final completion:** 2010-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2010-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00707681

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00707681, "Evaluation of Quality of Life and Survival With MS-20 in Patient With Advanced Hepatocellular Carcinoma (FDA IND 74572)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00707681. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*